Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms &am...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-05-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Online Access: | http://www.dovepress.com/analog-insulin-detemir-for-patients-with-type-1-and-type-2-diabetes-a--a3138 |
id |
doaj-0ed4823db64e443997f6940b7a08960c |
---|---|
record_format |
Article |
spelling |
doaj-0ed4823db64e443997f6940b7a08960c2020-11-24T21:35:27ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy1178-70072009-05-012009default3136Analog insulin detemir for patients with type 1 and type 2 diabetes: a reviewGregory E PetersonGregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms “insulin analogs,” “insulin detemir” and “long-acting insulin analog.”Results: Insulin detemir improves glycemic control, based on HbA1C reduction and fasting glucose levels, without increasing the risk of hypoglycemia and weight gain. Insulin detemir has lower glycemic variability, with less intra-subject variability in blood glucose levels in patients with type 1 and type 2 diabetes, without increasing the risk of hypoglycemia. When added to oral anti-diabetes agents (OADs) in type 2 diabetes, insulin detemir demonstrates superiority to other basal insulin options.Conclusion: Insulin detemir appears to provide better glycemic control with a lower risk of hypoglycemia and less weight gain in the treatment of patients with type 1 and type 2 diabetes.Keywords: type 1 diabetes, type 2 diabetes, insulin analogs, insulin detemir http://www.dovepress.com/analog-insulin-detemir-for-patients-with-type-1-and-type-2-diabetes-a--a3138 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gregory E Peterson |
spellingShingle |
Gregory E Peterson Analog insulin detemir for patients with type 1 and type 2 diabetes: a review Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
author_facet |
Gregory E Peterson |
author_sort |
Gregory E Peterson |
title |
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review |
title_short |
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review |
title_full |
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review |
title_fullStr |
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review |
title_full_unstemmed |
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review |
title_sort |
analog insulin detemir for patients with type 1 and type 2 diabetes: a review |
publisher |
Dove Medical Press |
series |
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
issn |
1178-7007 |
publishDate |
2009-05-01 |
description |
Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms “insulin analogs,” “insulin detemir” and “long-acting insulin analog.”Results: Insulin detemir improves glycemic control, based on HbA1C reduction and fasting glucose levels, without increasing the risk of hypoglycemia and weight gain. Insulin detemir has lower glycemic variability, with less intra-subject variability in blood glucose levels in patients with type 1 and type 2 diabetes, without increasing the risk of hypoglycemia. When added to oral anti-diabetes agents (OADs) in type 2 diabetes, insulin detemir demonstrates superiority to other basal insulin options.Conclusion: Insulin detemir appears to provide better glycemic control with a lower risk of hypoglycemia and less weight gain in the treatment of patients with type 1 and type 2 diabetes.Keywords: type 1 diabetes, type 2 diabetes, insulin analogs, insulin detemir |
url |
http://www.dovepress.com/analog-insulin-detemir-for-patients-with-type-1-and-type-2-diabetes-a--a3138 |
work_keys_str_mv |
AT gregoryepeterson analoginsulindetemirforpatientswithtype1andtype2diabetesareview |
_version_ |
1716693303934582784 |